文献速递皮肤肿瘤

肝移植受者后续非黑素瘤皮肤癌及免疫抑制的影响

Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients.
PubMed 文献 · J Am Acad Dermatol · 2018-01-04

这项回顾性研究纳入96例有移植后皮肤鳞状细胞癌、基底细胞癌或鲍恩病病史的肝移植受者,中位随访12.4年。53.1%发生141例后续非黑素瘤皮肤癌,皮肤光型I或II是二次肿瘤危险因素,停用钙调神经磷酸酶抑制剂有保护作用。

要点

  • 肝移植受者后续非黑素瘤皮肤癌很常见,5年发生风险49.4%,15年达88.4%。
  • 皮肤光型I或II者发生第二原发非黑素瘤皮肤癌风险升高(HR 2.556)。
  • 停用钙调神经磷酸酶抑制剂与后续非黑素瘤皮肤癌风险降低相关(HR 0.358)。

核心结论

  • 肝移植受者后续非黑素瘤皮肤癌非常常见。
  • 从以钙调神经磷酸酶抑制剂为基础的免疫抑制方案转换为以哺乳动物雷帕霉素靶蛋白抑制剂/抗代谢药为基础的方案可减少后续非黑素瘤皮肤癌。

研究设计与样本

  • 回顾性分析。
  • 纳入96例(76例男性)移植后有皮肤鳞状细胞癌、基底细胞癌或鲍恩病病史的肝移植受者。
  • 肝移植后中位随访12.4年(范围1.5-27.8年)。

主要发现

  • 首次非黑素瘤皮肤癌后中位随访6.4年(范围0.17-22.1年)。
  • 52例(53.1%)发生141例后续非黑素瘤皮肤癌,基底细胞癌与鳞状细胞癌比例为1.8:1。
  • 发生第二原发非黑素瘤皮肤癌的风险:1年13.7%、2年28.4%、5年49.4%、10年65.7%、15年88.4%。
  • 多因素分析显示皮肤光型I或II(对比III或IV)是发生第二原发非黑素瘤皮肤癌的显著危险因素(HR 2.556;95%CI 1.45-4.48;P=.001)。
  • 停用钙调神经磷酸酶抑制剂有显著保护作用(HR 0.358;95%CI 0.142-0.902;P=.029)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 回顾性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nonmelanoma skin cancers (NMSCs) are the most frequent cancers in solid organ transplant recipients, with a high rate of subsequent tumors. OBJECTIVES: To describe subsequent NMSCs in a large cohort of liver transplant recipients (LTRs) with long follow-up and analyze the factors influencing it, including immunosuppressive regimen. METHODS: A total of 96 LTRs (76 male) with a personal post-transplant history of squamous cell carcinoma, basal cell carcinoma or Bowen's disease were included, with a median follow-up of 12.4 years (range, 1.5-27.8) after liver transplantation. RESULTS: The median follow-up after first NMSC was 6.4 years (range, 0.17-22.1). In all, 52 patients (53.1%) developed 141 subsequent NMSCs with a basal cell carcinoma-to-squamous cell carcinoma ratio of 1.8:1. The actuarial risk for development of a second NMSC was 13.7% at 1 year, 28.4% at 2 years, 49.4% at 5 years, 65.7% at 10 years, and 88.4% at 15 years. Multivariate analysis found that skin phototype I or II (vs III or IV) was a significant risk factor for development of a second NMSC (hazard ratio, 2.556; 95% confidence interval, 1.45-4.48; P = .001), whereas withdrawal of calcineurin inhibitors was significantly protective (hazard ratio, 0.358; 95% confidence interval, 0.142-0.902; P = .029). LIMITATIONS: Retrospective analysis. CONCLUSIONS: Subsequent NMSCs are very frequent in LTRs, and conversion from a calcineurin inhibitor-based immunosuppressive regimen to a mammalian target of rapamycin inhibitor/antimetabolite-based immunosuppressive regimen can reduce subsequent NMSCs.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Funk-Debleds P, Ducroux E, Guillaud O, et al. Subsequent nonmelanoma skin cancers and impact of immunosuppression in liver transplant recipients. J Am Acad Dermatol. 2018. PMID: 29307647. doi:10.1016/j.jaad.2017.12.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。